To explore the effects of PI3K/Akt pathway mutation status in COAD patients at the DNA and RNA levels, we analyzed the top 20 most frequently mutated genes in the TCGA-COAD and immunotherapy cohorts. This evidence concerns the gene AKT1 and colon adenocarcinoma.